Issue Date: May 29, 2017
Iterum raises funds for new antibiotic
The biotech firm Iterum Therapeutics has raised $65 million in a series B investment round. The cash will help the company complete a Phase III clinical trial of sulopenem, an antibiotic it is developing to treat Gram-negative multi-drug-resistant infections. Iterum was founded in 2015 to license sulopenem from its discoverer, Pfizer. It plans to file a New Drug Application with FDA by the end of 2019.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society